Acer Therapeutics — Opexa Therapeutics — Q4 2013 Earnings Presentation
9 slides from Acer Therapeutics's earnings presentation, Feb 28, 2014
Slide 1: Q4 2013 Earnings Call: Precision Immunotherapy
Opexa Therapeutics, Inc. NASDAQ: OPXA Q4 2013 Earnings Call Precision Immunotherapy February 27, 2014 The Woodlands, TX
Slide 2: Forward-Looking Statements
Forward-Looking Statements This earnings presentation contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements contained in this e
Slide 3: Opexa's Mission
Opexa’s Mission To lead the field of Precision ImmunotherapyTM by aligning the interests of patients, employees and shareholders. 3
Slide 4: Strong 2013: Positions Opexa well for 2014
Strong 2013: Positions Opexa well for 2014 Clinical As of February 27, 2014, enrolled over 80% of the total number of patients expected to be enrolled in the Phase IIb “Abili-T” clinical study of Tcelna (imilecleucel-T) in patients with Secondary Progressive MS Furthered the accumulation of comprehe
Slide 5: Tcelna in Secondary Progressive MS
Tcelna in Secondary Progressive MS 450,000 MS Patients in North America; 30-45 % with SPMS SPMS Market Size: $7 Billion (est.) Market Size: $15 Billion Other MS Patients (RRMS, PPMS) Cost per year (Feb 2014): Copaxone -$61k per patient per year Gilenya- $63k per patient per year Source: PriceRx Pote
Slide 6: Abili-T: Landmark trial in SPMS
Abili-T : Landmark trial in SPMS Abili-T Phase IIb clinical trial in SPMS is ongoing Double-blind, 1:1 randomized, placebo-controlled Inclusion criteria: Secondary Progressive MS with EDSS of 3 to 6 Immune Monitoring program conducted on a blinded basis Fast Track designation granted by FDA for Tcel
Slide 7: Immune Monitoring Program: Biomarker analysis
Immune Monitoring Program: Biomarker analysis Assessment of 180 SPMS patient samples (both placebo and active) may provide valuable information on directional movement of antiinflammatory and pro-inflammatory biomarkers Purpose Investigate the impact of Tcelna® treatment on systemic immunity Further
Slide 8: Financials
Financials Income Statement 2013 2012 Option Revenue $1,266,611 ‐ Research & Development $9,181,090 $6,318,476 General & Administrative $3,670,769 $2,508,541 Operating Loss $(11,923,006) $(9,133,791) Net Loss $(16,656,325) $(8,930,833) Basic & diluted Loss/Share $(1.25) $(1.54) Balance Sheet Details
Slide 9: Opexa Highlights
Opexa Highlights MS franchise progressing Expecting to complete enrollment of Abili-T trial in Q2 2014 Strong potential partner in Merck Serono Immune Monitoring Program generating comprehensive data set to support potential Phase III and commercialization plans Seeking to Leverage ImmPath® T-cell p